(Q90045711)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31506592%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

title

Refining the understanding of typical Alzheimer disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31506592%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31506592%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

publication date

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31506592%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

published in

Nature Reviews Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31506592%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31506592%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31506592%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

page(s)

623-624

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31506592%20AND%20SRC:MED&resulttype=core&format=json

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

10 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41582-019-0259-0

7 January 2021

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-019-0259-0

7 January 2021

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

1 reference

https://api.crossref.org/works/10.1038%2FS41582-019-0259-0

7 January 2021

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-019-0259-0

7 January 2021

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-019-0259-0

7 January 2021

Cognitive heterogeneity in probable Alzheimer disease: Clinical and neuropathologic features

1 reference

https://api.crossref.org/works/10.1038%2FS41582-019-0259-0

7 January 2021

Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-019-0259-0

7 January 2021

In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-019-0259-0

7 January 2021

Revolution of Alzheimer Precision Neurology Passageway of Systems Biology and Neurophysiology.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-019-0259-0

7 January 2021

10.1038/S41582-019-0259-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31506592%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

1 reference